Previous 10 | Next 10 |
RADNOR, Pa., June 24, 2020 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced it will host a webinar featuring a clinical update and comme...
Thanks to exchange-traded funds (ETFs), investors don’t have to be tied to one specific stock. Biotech ETFs allow market participants to invest in multiple biotech companies via one vehicle. The life science sector certainly holds a risk factor, and ETFs are a good way to enter th...
RADNOR, Pa., June 22, 2020 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced that management will present at SVB Leerink’s CybeRx Seri...
RADNOR, Pa., June 02, 2020 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS), (“Marinus” or the “Company”) today announced the closing of an underwritten public offering of 18,400,000 shares of common stock at a public offering price of $2.50 per s...
ARCA biopharma (NASDAQ: ABIO ) -28% . More news on: ARCA biopharma, Inc., ToughBuilt Industries, Inc., Canopy Growth Corporation, Stocks on the move, , Read more ...
Marinus Pharmaceuticals (NASDAQ: MRNS ) has priced its public offering of 16M common shares at $2.50/share, for expected gross proceeds of ~$40M. More news on: Marinus Pharmaceuticals, Inc., Healthcare stocks news, , Read more ...
RADNOR, Pa., May 28, 2020 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) (“Marinus” or the “Company”), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced that it...
Investment Thesis Fueled by a string of catalysts, the shares of Axsome Therapeutics, Inc. ( AXSM ) rose exponentially last year. After achieving the major milestones last year, the stock has declined so far as its net losses keep piling up amid the growing R&D expenditure. However, th...
Marinus Pharmaceuticals, Inc. (MRNS) Q1 2020 Results Earnings Conference Call May 4, 2020, 08:30 AM ET Company Participants Sasha Damouni Ellis - Vice President, Investor Relations and Corporate Communications Scott Braunstein - Chief Executive Officer Joe Hulihan - Chief Medica...
Marinus Pharmaceuticals (NASDAQ: MRNS ) provides an update on its clinical development activities. More news on: Marinus Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Marinus Pharmaceuticals Inc. Company Name:
MRNS Stock Symbol:
NASDAQ Market:
Marinus Pharmaceuticals Inc. Website:
Marinus Pharmaceuticals , Inc. (Nasdaq:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release financial results for the second quarter ended June 30, 2024 on August 13, 2024. The Company will h...
MRNS Investors Have Opportunity to Lead Marinus Pharmaceuticals, Inc. Securities Lawsuit Filed by the Schall Law Firm PR Newswire LOS ANGELES , July 24, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing ...
Marinus Pharmaceuticals , Inc. (Nasdaq:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that the China National Medical Products Administration (NMPA) has approved ganaxolone oral suspension for the treatment of ...